The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Open accessAbstract
Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Still, often phenotypes such as drug response observed in vitro have been unable to mirror in vivo models, likely due to factors missing in the tumor microenvironment that are absent from homogeneous cell lines cultures such as stromal and immune cells (Beaufort et al., 2014).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Beaufort et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 1×
“Sequence analysis and variant verification was performed as described previously [26,27].”
MethodThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“analysed genomic data for 47 ovarian cancer cell lines from the CCLE collection [13] for genetic similarity to highgrade serous ovarian carcinomas from the TCGA data [4,57].”
BackgroundIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
The Massachusetts Institute of Technology
Endowed, S. C. F. (1999) · Anthropology News · doi:10.1111/an.1999.40.2.6 · Cited by 3,132
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
BackgroundOne Hundred and Twenty-Seven Cultured Human Tumor Cell Lines Producing Tumors in Nude Mice23
Fogh, J., Fogh, J. M., & Orfeo, T. (1977) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/59.1.221 · Cited by 1,599
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484 · cited 1×
“The remaining histiotypes are mucinous, endometrioid and clear cell [3].”
BackgroundNovel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,458 · cited 7×
“We used the expression data for 267 malignant ovarian carcinomas (GSE9891) [11] to determine the clinical significance of the morphological subtypes seen in our cell lines.”
BackgroundMethodInfluentialEvaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,457 · cited 2×
“Comparison of our results with the two earlier studies [31,57] shows similar prediction for HGS and some discrepancies for the non-serous cell lines.”
BackgroundResultNaba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354 · cited 1×
“[71–73] (i.”
Overview of the Matrisome--An Inventory of Extracellular Matrix Constituents and Functions
Hynes, R. O., & Naba, A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004903 · Cited by 1,349
Forshew, T., Murtaza, M., Parkinson, C., Gale, D. G., Tsui, D. W. Y., Kaper, F., Dawson, S., Piskorz, A., Jimenez‐Liñan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,308 · cited 2×
“48 (Fluidigm CA, USA) according to manufacturer’s protocol as described previously [26].”
MethodDaynes, R. A., Araneo, B. A., Ershler, W. B., Maloney, C., Li, G. Z., & Ryu, S. Y. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.12.5219 · Cited by 1,264
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Zöller, M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3023 · Cited by 1,152
A novel and universal method for microRNA RT-qPCR data normalization
Mestdagh, P., Van Vlierberghe, P., De Weer, A., Muth, D., Westermann, F., Speleman, F., & Vandesompele, J. (2009) · Genome Biology · doi:10.1186/gb-2009-10-6-r64 · Cited by 1,079 · cited 1×
“[19] (see also File S1).”
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 815 · cited 1×
“High-grade serous (HGS) carcinoma represents 80% of ovarian cancers and is defined by TP53 mutation (96%), homologous recombination DNA repair defects (,50%), CCNE1 amplification and genomic instability [4–6].”
BackgroundBapat, S. A., Mali, A. M., Koppikar, C. B., & Kurrey, N. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3931 · Cited by 770
How to Detect and Handle Outliers
Crosby, T. A., Iglewicz, B., & Hoaglin, D. C. (1994) · Technometrics · doi:10.2307/1269377 · Cited by 764
The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications
Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., & Friess, H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.115 · Cited by 662 · cited 1×
“Indeed, stromal fibroblasts play an important role in tumourigenesis and prognosis in several cancer types [75–77].”
BackgroundLo, H., Hsu, S.-C., Xia, W., Cao, X., Shih, J., Wei, Y., Abbruzzese, J. L., Hortobágyi, G. N., & Hung, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0575 · Cited by 647 · cited 2×
“Epithelial to mesenchymal transition (EMT) is typically defined by the acquisition of a Spindle morphology and up-regulation of mesenchymal markers such as SNAIL, ZEB, TWIST, VIM, FN1 and CAV1 [66–70].”
BackgroundPrognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M. S., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 587 · cited 2×
“Furthermore, we see a small overlap between our in vitro morphology genes with the CLOVAR subtype signature of 100 genes [74] which is enriched for genes that are up in the CLOVAR Mesenchymal subtype that are also high in the Spindle subtype (12/19 overlapping genes).”
BackgroundResultHamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., Whang‐Peng, J., Rogan, A. M., Green, W. R., & Ozols, R. F. (1983) · PubMed · Cited by 539
Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 494 · cited 1×
“Indeed, stromal fibroblasts play an important role in tumourigenesis and prognosis in several cancer types [75–77].”
BackgroundAlvero, A. B., Chen, R., Fu, H., Montagna, M. K., Schwartz, P. E., Rutherford, T., Silasi, D., Steffensen, K. D., Waldstrøm, M., Visintin, I., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7533 · Cited by 488 · cited 1×
“The literature suggests that CD44 high tumour cells display increased self-renewal, migration and therapy resistance and are suggested to be cancer initiating cells (CIC) [83– 86].”
BackgroundEarly Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462 · cited 1×
“By contrast, low-grade serous carcinomas are TP53 wildtype and show frequently activating RAS pathway mutations [7,8].”
BackgroundPathogenesis of Ovarian Cancer
Kurman, R. J., & Shih, I. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460 · cited 1×
“By contrast, low-grade serous carcinomas are TP53 wildtype and show frequently activating RAS pathway mutations [7,8].”
BackgroundExpression of Vascular Endothelial Growt Factor and Its Receptors fit and KDR in Ovarian Carcinoma
Boocock, C. A., Jones, D. S., Sharkey, A., McLaren, J. F., Barker, P. J., Wright, K., Twentyman, P. R., & Smith, S. K. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.7.506 · Cited by 456
The tumor microenvironment is a dominant force in multidrug resistance
Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 455 · cited 2×
“by decreasing drug concentrations through increased interstitial fluid pressure, 3D structure or by activating cellular pathways through ECM-Integrin binding, the so-called cell adhesion-mediated drug resistance (CAM-DR) [78].”
BackgroundSieuwerts, A. M., Kraan, J., Bolt, J., van der Spoel, P., Elstrodt, F., Schutte, M. E. M., Martens, J. W. M., Gratama, J.-W. C., Sleijfer, S., & Foekens, J. A. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn419 · Cited by 433
Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Steg, A. D., Bevis, K. S., Katre, A. A., Ziebarth, A., Dobbin, Z. C., Alvarez, R. D., Zhang, K., Conner, M. G., & Landen, C. N. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2188 · Cited by 359 · cited 1×
“Also in ovarian cancer, increased density of CD44 positive cells was associated with chemotherapy resistance [87,88].”
BackgroundMolecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling
Jansen, M. P. H. M., Foekens, J. A., van Staveren, I. L., Dirkzwager-Kiel, M. M., Ruigrok-Ritstier, K., Look, M. P., Gelder, M. E. M., Sieuwerts, A. M., Portengen, H., Dorssers, L. C. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.145 · Cited by 337 · cited 1×
“In earlier studies we also observed an association between (TGFbeta-induced) ECM remodeling during EMT and chemotherapy resistance in ovarian cancer [18,79] as well as endocrine therapy resistance in breast cancer [80–82].”
BackgroundComparative properties of five human ovarian adenocarcinoma cell lines.
Buick, R. N., Pullano, R., & Trent, J. M. (1985) · PubMed · Cited by 326
Kompier, L. C., Lurkin, I., van der Aa, M. N. M., van Rhijn, B. W. G., van der Kwast, T., & Zwarthoff, E. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013821 · Cited by 326
Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Marcotte, R., Brown, K. R., Suárez, F., Sayad, A., Karamboulas, K., Krzyzanowski, P. M., Sircoulomb, F., Medrano, M., Fedyshyn, Y., Koh, J. L. Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0224 · Cited by 303 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
BackgroundCharacterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.
Bénard, J., Silva, J. D., Blois, M. C. D., Boyer, P. J. J., Duvillard, P., Chiric, E., & RIOU, G. F. (1985) · PubMed · Cited by 287
Prognostic relevance of cancer-associated fibroblasts in human cancer
Paulsson, J., & Micke, P. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.02.006 · Cited by 275 · cited 1×
“Indeed, stromal fibroblasts play an important role in tumourigenesis and prognosis in several cancer types [75–77].”
BackgroundCharacterization and properties of nine human ovarian adenocarcinoma cell lines.
Langdon, S. P., Lawrie, S. S., Hay, F. G., Hawkes, M. M., McDonald, A. W., Hayward, I. P., Schol, D. J., Hilgers, J., Leonard, R. C., & Smyth, J. F. (1988) · PubMed · Cited by 269
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C. M., Prentice, L., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072162 · Cited by 254 · cited 3×
“Comparison of our results with the two earlier studies [31,57] shows similar prediction for HGS and some discrepancies for the non-serous cell lines.”
MethodResultKorch, C. T., Spillman, M. A., Jackson, T. A., Jacobsen, B. M., Murphy, S. K., Lessey, B. A., Jordan, V. C., & Bradford, A. P. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.017 · Cited by 249 · cited 2×
“to have a variable STR profile with multiple peaks which may indicate cross-contamination [29].”
BackgroundLatifi, A., Abubaker, K., Castrechini, N., Ward, A. C., Liongue, C., Dobill, F., Kumar, J., Thompson, E. W., Quinn, M. A., Findlay, J. K., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23199 · Cited by 243 · cited 1×
“Also in ovarian cancer, increased density of CD44 positive cells was associated with chemotherapy resistance [87,88].”
BackgroundHills, C. A., Kèlland, L. R., Abel, G., Siracký, J., Wilson, A., & Harrap, K. R. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.108 · Cited by 183
CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival
Meng, E., Long, B. J., Sullivan, P., McClellan, S., Finan, M. A., Reed, E., Shevde, L. A., & Rocconi, R. P. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9482-4 · Cited by 180
Helleman, J., Jansen, M. P. H. M., Ruigrok-Ritstier, K., van Staveren, I. L., Look, M. P., Gelder, M. E. M., Sieuwerts, A. M., Klijn, J. G. M., Sleijfer, S., Foekens, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0555 · Cited by 178 · cited 1×
“In earlier studies we also observed an association between (TGFbeta-induced) ECM remodeling during EMT and chemotherapy resistance in ovarian cancer [18,79] as well as endocrine therapy resistance in breast cancer [80–82].”
BackgroundThe Changing View of High-Grade Serous Ovarian Cancer
Berns, E. M. J. J., & Bowtell, D. D. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3911 · Cited by 172 · cited 2×
“[5], 53 genes that are often mutated or amplified in ovarian cancer were selected for analyses (see supplement methods in File S1 for the list of genes).”
BackgroundMethodHamilton, T. C., Young, R. C., & Ozols, R. F. (1984) · PubMed · Cited by 167
Molecular profiling of platinum resistant ovarian cancer
Helleman, J., Jansen, M. P. H. M., Span, P. N., van Staveren, I. L., Massuger, L. F. A. G., Gelder, M. E. M., Sweep, F. C. G. J., Ewing, P. C., van der Burg, M. E. L., Stoter, G., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21599 · Cited by 165 · cited 2×
“Total RNA was isolated from lysates as previously described [18].”
BackgroundMethodTargeted next-generation sequencing: A novel diagnostic tool for primary immunodeficiencies
Nijman, I. J., van Montfrans, J. M., Hoogstraat, M., Boes, M. L., van de Corput, L., Renner, E. D., van Zon, P. H. A., van Lieshout, S., Elferink, M., van der Burg, M., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.032 · Cited by 160 · cited 1×
“We determined the amplification of CCNE1, MYC, TPX2 and ERBB2 by comparing the sequencing coverage for each exon to the median overall coverage [55].”
MethodHyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts
Auzenne, E. J., Ghosh, S. C., Khodadadian, M., Rivera, B., Farquhar, D., Price, R. E., Ravoori, M. K., Kundra, V., Freedman, R. S., & Klostergaard, J. (2007) · Neoplasia · doi:10.1593/neo.07229 · Cited by 159
van den Berg‐Bakker, C. A. M., Hagemeijer, A., Franken‐Postma, E. M., Smit, V. T. H. B. M., Kuppen, P. J. K., Claasen, H. H. V. R., Cornelisse, C. J., & Schrier, P. I. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530415 · Cited by 140
Hollestelle, A., Peeters, J. K., Smid, M., Timmermans, M. A. M., Verhoog, L. C., Westenend, P. J., Heine, A. A. J., Chan, A. B., Sieuwerts, A. M., Wiemer, E. A. C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2415-3 · Cited by 138 · cited 2×
“Epithelial to mesenchymal transition (EMT) is typically defined by the acquisition of a Spindle morphology and up-regulation of mesenchymal markers such as SNAIL, ZEB, TWIST, VIM, FN1 and CAV1 [66–70].”
BackgroundWolf, C. R., Hayward, I. P., Lawrie, S. S., BUCKTON, K. E., McIntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R., & Smyth, J. F. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390607 · Cited by 135
DelloRusso, C., Welcsh, P. L., Wang, W., Garcia, R. L., King, M., & Swisher, E. M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0234 · Cited by 134
Yasuaki, K. U. B. O., Kaidzu, S., Nakajima, I., Takenouchi, K., & NAKAMURA, F. (2000) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1071-2690(2000)036 · Cited by 133
Zhang, X., Liu, G., Kang, Y., Dong, Z., Qian, Q., & Ma, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057692 · Cited by 129 · cited 2×
“Epithelial to mesenchymal transition (EMT) is typically defined by the acquisition of a Spindle morphology and up-regulation of mesenchymal markers such as SNAIL, ZEB, TWIST, VIM, FN1 and CAV1 [66–70].”
BackgroundIntegrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Mismatch repair and treatment resistance in ovarian cancer
Helleman, J., van Staveren, I. L., Dinjens, W. N. M., van Kuijk, P. F., Ruigrok-Ritstier, K., Ewing, P. C., van der Burg, M. E., Stoter, G., & Berns, E. M. J. J. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-201 · Cited by 99 · cited 2×
“OAW42 shows no TP53 mutation but a PIK3CA and a BRCA1 mutation and both SKOV3 cell lines are MSI which is more often seen in the mucinous and endometrioid subtypes [54].”
BackgroundLau, D. H., Lewis, A. D., Ehsan, M. N., & Sikic, B. I. (1991) · PubMed · Cited by 97
Lurkin, I., Stoehr, R., Hurst, C. D., van Tilborg, A. A. G., Knowles, M. A., Hartmann, A., & Zwarthoff, E. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008802 · Cited by 94 · cited 1×
“SNaPshot analysis was performed as described previously [20– 22] using an Applied Biosystems SNaPshot Multiplex Kit.”
MethodHelleman, J., Smid, M., Jansen, M. P. H. M., van der Burg, M. E. L., & Berns, E. M. J. J. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.01.010 · Cited by 82 · cited 1×
“In earlier studies we also observed an association between (TGFbeta-induced) ECM remodeling during EMT and chemotherapy resistance in ovarian cancer [18,79] as well as endocrine therapy resistance in breast cancer [80–82].”
BackgroundSheppard, K. E., Cullinane, C. M., Hannan, K. M., Wall, M., Chan, J., Barber, F., Foo, J. H., Cameron, D. P., Neilsen, A., Ng, P. Y., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.007 · Cited by 81 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
BackgroundMer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme
Wang, Y., Moncayo, G. E., Morin, P., Xue, G., Grzmil, M., Lino, M. M., Clément‐Schatlo, V., Frank, S., Merlo, A. U., & Hemmings, B. A. (2012) · Oncogene · doi:10.1038/onc.2012.104 · Cited by 79 · cited 2×
“The in vitro Round morphology has been associated with the side population that shares characteristics with tumour stem cells of cervical and gastric tumour cell lines [59,60] as well as with socalled amoeboid migration [61–65].”
Backgroundcis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
Kuppen, P. J. K., Schuitemaker, H., Veer, L. V. ‘., de Bruijn, E. A., van Oosterom, A. T., & Schrier, P. I. (1988) · PubMed · Cited by 76
Saito, K., Ozawa, Y., Hibino, K., & Ohta, Y. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-04-0310 · Cited by 76 · cited 2×
“The in vitro Round morphology has been associated with the side population that shares characteristics with tumour stem cells of cervical and gastric tumour cell lines [59,60] as well as with socalled amoeboid migration [61–65].”
BackgroundTaddei, M. L., Parri, M., Angelucci, A., Bianchini, F., Marconi, C., Giannoni, E., Raugei, G., Bologna, M., Calorini, L., & Chiarugi, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0298 · Cited by 76 · cited 2×
“The in vitro Round morphology has been associated with the side population that shares characteristics with tumour stem cells of cervical and gastric tumour cell lines [59,60] as well as with socalled amoeboid migration [61–65].”
BackgroundHogan, T. F., Citrin, D. L., Johnson, B. M., Nakamura, S., Davis, T. E., & Borden, E. C. (1978) · Cancer · doi:10.1002/1097-0142(197811)42:5 · Cited by 72
Wilson, A. P. (1984) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/72.3.513 · Cited by 72
Gupta, N., Xu, Z., El‐Sehemy, A., Steed, H. L., & Fu, Y. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.03.019 · Cited by 71
Harakaľová, M., Mokrý, M., Hrdličková, B., Renkens, I., Duran, K. J., van Roekel, H. S., Lansu, N. R., van Roosmalen, M. J., de Bruijn, E., Nijman, I. J., et al. (2011) · Nature Protocols · doi:10.1038/nprot.2011.396 · Cited by 70 · cited 1×
“Processing of samples for sequencing on the SOLiD5500 sequencing platform (Life Technologies) was performed on a Sciclone NGS liquid handling robot (Perkin Elmer), based on the protocol for manual library preparation [23].”
MethodZheng, H., Cai, Y. D., Wang, Y. D., Cui, X., Xie, T., Li, W. J., Peng, L., Zhang, Y., Wang, Z. Q., Wang, J., et al. (2012) · Oncogene · doi:10.1038/onc.2012.126 · Cited by 69 · cited 2×
“Epithelial to mesenchymal transition (EMT) is typically defined by the acquisition of a Spindle morphology and up-regulation of mesenchymal markers such as SNAIL, ZEB, TWIST, VIM, FN1 and CAV1 [66–70].”
BackgroundMutation discovery by targeted genomic enrichment of multiplexed barcoded samples
Nijman, I. J., Mokrý, M., van Boxtel, R., Toonen, P. W., de Bruijn, E., & Cuppen, E. P. J. G. (2010) · Nature Methods · doi:10.1038/nmeth.1516 · Cited by 67 · cited 1×
“[24]) using a custom designed enrichment kit.”
RhoB regulates cell migration through altered focal adhesion dynamics
Vega, F. M. D. L., Colomba, A., Reymond, N., Thomas, M., & Ridley, A. J. (2012) · Open Biology · doi:10.1098/rsob.120076 · Cited by 64 · cited 2×
“The in vitro Round morphology has been associated with the side population that shares characteristics with tumour stem cells of cervical and gastric tumour cell lines [59,60] as well as with socalled amoeboid migration [61–65].”
BackgroundStefano, I. D., Battaglia, A., Zannoni, G. F., Prisco, M. G., Fattorossi, A., Travaglia, D., Baroni, S., Renier, D., Scambia, G., Ferlini, C., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1462-2 · Cited by 58 · cited 4×
“Response curves were generated for Carboplatin, Cisplatin, Oxaliplatin, Doxorubicin and 5-Fluorouracil (Intravenous solutions, Pharmachemie, The Netherlands), Paclitaxel (Intravenous solution, Ebewe Pharma, Austria), Docetaxel (dissolved in DMSO, Sigma), and Gemcitabin (for intravenous use, dissolved in PBS, Sun Pharm…”
BackgroundInfluentialGenotypic and Phenotypic Characterization of Side Population of Gastric Cancer Cell Lines
Schmuck, R. B., Warneke, V. S., Behrens, H., Simon, É., Weichert, W., & Röcken, C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.043 · Cited by 57 · cited 1×
“The in vitro Round morphology has been associated with the side population that shares characteristics with tumour stem cells of cervical and gastric tumour cell lines [59,60] as well as with socalled amoeboid migration [61–65].”
BackgroundThe role of targeted therapy in ovarian cancer
Banerjee, S. N., & Kaye, S. B. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70155-1 · Cited by 56 · cited 1×
“Despite testing of diverse treatment strategies and new cytotoxic agents, optimal primary therapy and survival rates have not substantially changed since the introduction of platinum and taxane treatment [1–3].”
BackgroundRamirez-Ardila, D. E., Helmijr, J., Look, M. P., Lurkin, I., Ruigrok-Ritstier, K., Laere, S. V., Dirix, L. Y., Sweep, F. C. G. J., Span, P. N., Linn, S. C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2529-7 · Cited by 53
de Toledo, M., Anguille, C., Roger, L., Roux, P., & Gadéa, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048344 · Cited by 51
Helleman, J., Jansen, M. P. H. M., Burger, C. W., van der Burg, M. E. L., & Berns, E. M. J. J. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.10.016 · Cited by 48 · cited 1×
“In earlier studies we also observed an association between (TGFbeta-induced) ECM remodeling during EMT and chemotherapy resistance in ovarian cancer [18,79] as well as endocrine therapy resistance in breast cancer [80–82].”
BackgroundMapping of chromosome 3p deletions in human epithelial ovarian tumors
Lounis, H., Mes‐Masson, A., Dion, F., Bradley, W. E. C., Seymour, R. J., Provencher, D. M., & Tonin, P. N. (1998) · Oncogene · doi:10.1038/sj.onc.1202152 · Cited by 46
Four human breast cancer cell lines with biallelic inactivating α-catenin gene mutations
Hollestelle, A., Elstrodt, F., Timmermans, M. A. M., Sieuwerts, A. M., Klijn, J. G. M., Foekens, J. A., den Bakker, M. A., & Schutte, M. E. M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0545-4 · Cited by 40 · cited 1×
“These three morphological phenotypes were previously observed in multiple types of cancer cell lines including cervical, gastric, prostate, colorectal, lung and glioblastoma [59–70] and a panel of 54 breast cancer cell lines [58].”
BackgroundSorting and identification of side population cells in the human cervical cancer cell line HeLa
Qi, W., Zhao, C., Zhao, L., Liu, N., Li, X., Yu, W., & Wei, L. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-3 · Cited by 40 · cited 1×
“The in vitro Round morphology has been associated with the side population that shares characteristics with tumour stem cells of cervical and gastric tumour cell lines [59,60] as well as with socalled amoeboid migration [61–65].”
BackgroundMackillop, W. J., Trent, J. M., Stewart, S. S., & Buick, R. N. (1983) · PubMed · Cited by 31
Marth, C., Cronauer, M. V., Doppler, W., Öfner, D., Ullrich, A., & Daxenbichler, G. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500114 · Cited by 31
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro
Karlan, B. Y., Amin, W., Band, V., Zurawski, V. R., & Littlefield, B. A. (1988) · Gynecologic Oncology · doi:10.1016/0090-8258(88)90276-4 · Cited by 26
Characterisation of seven human ovarian tumour cell lines
Wilson, A., Dent, M. F., Pejovic, T. B., Hubbold, L., & Radford, H. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.428 · Cited by 22
Itamochi, H., Yoshida, T., Walker, C. L., Bartholomeusz, C., Aoki, D., Ishihara, H., Suzuki, N., Kigawa, J., Terakawa, N., & Ueno, N. T. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.003 · Cited by 22 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
BackgroundLau, D. H. M., Ross, K. L., & Sikic, B. I. (1990) · PubMed · Cited by 16
First line therapy: have we made any improvement?
Bookman, M. A. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70153-8 · Cited by 5 · cited 1×
“Despite testing of diverse treatment strategies and new cytotoxic agents, optimal primary therapy and survival rates have not substantially changed since the introduction of platinum and taxane treatment [1–3].”
BackgroundDifferential hRad17 expression by histologic subtype of ovarian cancer
Young, J. L., Koon, E. C., Kwong, J., Welch, W. R., Muto, M. G., Berkowitz, R. S., & Mok, S. C. (2011) · Journal of Ovarian Research · doi:10.1186/1757-2215-4-6 · Cited by 2 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,395
The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation
Liu, T., Wei, Q., Jin, J., Luo, Q., Liu, Y., Yu, Y., Cheng, C., Li, L., Pi, J., Si, Y., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa048 · Cited by 751
“Albeit A2780 and SKOV3 are most frequently used for ovarian cancer studies, particularly for high-grade serous ovarian cancer, they are probably originated from endometrioid or clear cell ovarian cancer (39).”
BackgroundHigh-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M. A., Fu, L., Goyeneche, A. A., Gao, Z., & Telleria, C. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 685
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Medico, E., Russo, M., Picco, G., Cancelliere, C., Valtorta, E., Corti, G., Buscarino, M., Isella, C., Lamba, S., Martinoglio, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8002 · Cited by 302
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Main, H. G., Xie, J., Lantvit, D. D., Cárdenas, H., Fang, F., Liu, Y., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.040 · Cited by 214
Metadata
- Authors
- Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., Koudijs, M. J., Brenton, J. D., Berns, E. M. J. J., & Helleman, J.
- Affiliations
- Erasmus MC Cancer Institute (NL)
- University of Cambridge (GB)
- University Medical Center Utrecht (NL)
- Corresponding author
- Berns, Els M. J. J.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-09-17
- Volume
- 9
- Issue
- 9
- Pages
- e103988
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4167545
- OpenAlex
- W2015030879
- Cited by
- 403
- References
- 89
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 30 · 2023: 48 · 2022: 38 · 2021: 54 · 2020: 52 · 2019: 41 · 2018: 27 · 2017: 28 · 2016: 25 · 2015: 21
- FWCI
- 29.95
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-03-23)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Cancer Research UK (15601)
- Universitair Medisch Centrum Utrecht
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- epithelial ovarian cancer, ovarian cancer cell lines, morphological subtypes, high-grade serous carcinoma, low-grade serous carcinoma, tumor heterogeneity, metastasis, prognosis, drug response, preclinical models
- MeSH terms
- Carcinoma, Ovarian Epithelial, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Gene Expression Regulation, Neoplastic, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
